Jinliang Zhang , Weijia Cao , Le Yu , Yanyan Cui , Kecui Xu , Jun Tian , Sebastian Hogl , Hitto Kaufmann , Weichang Zhou , Sherry Gu
{"title":"逐步强化细胞培养工艺,实现高生产率和高成本效益的马布卡林™双特异性药物商业化生产","authors":"Jinliang Zhang , Weijia Cao , Le Yu , Yanyan Cui , Kecui Xu , Jun Tian , Sebastian Hogl , Hitto Kaufmann , Weichang Zhou , Sherry Gu","doi":"10.1016/j.bej.2024.109476","DOIUrl":null,"url":null,"abstract":"<div><p>Process intensification and media optimization, as a crucial step for improving productivity and manufacturing cost of goods (COG), set the stage for commercialization readiness and redefine the landscape for patient access. This study described a stepwise approach to explore different intensified fed-batch processes along with optimized cell culture media for the production of a Mabcalin™ bispecifics. Initially, by leveraging perfusion expansion, intensified fed-batch (IFB) with an inoculation density of 10.3 × 10<sup>6</sup> cells/mL was developed to produce 6.1 g/L of products, compared to 3.9 g/L from the original traditional fed-batch (TFB). Following the IFB conversion, a high-performing production medium, MagniCHO™, was chosen to substitute the original one, which further boosted the titer to 9.1 g/L. The result underscored the significance of developing an optimized cell culture media for intensified cultivation. Furthermore, the approach of ultra-intensified intermittent-perfusion fed-batch was utilized, raising the seeding density to 73.6 × 10<sup>6</sup> cells/mL. A final harvest titer of 24.5 g/L was recorded. Additionally, manufacturing COG was calculated to evaluate how process intensification could lead to improved manufacturing cost-effectiveness, with up to 71 % COG reduction attainable with the UI-IPFB process. This study demonstrated that even for difficult-to-express modalities, applying a strategic development approach including process intensification and media optimization could effectively improve manufacturing efficiency and COG competitiveness.</p></div>","PeriodicalId":8766,"journal":{"name":"Biochemical Engineering Journal","volume":"211 ","pages":"Article 109476"},"PeriodicalIF":3.7000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Stepwise cell culture process intensification for high-productivity and cost-effective commercial manufacturing of a Mabcalin™ bispecifics\",\"authors\":\"Jinliang Zhang , Weijia Cao , Le Yu , Yanyan Cui , Kecui Xu , Jun Tian , Sebastian Hogl , Hitto Kaufmann , Weichang Zhou , Sherry Gu\",\"doi\":\"10.1016/j.bej.2024.109476\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Process intensification and media optimization, as a crucial step for improving productivity and manufacturing cost of goods (COG), set the stage for commercialization readiness and redefine the landscape for patient access. This study described a stepwise approach to explore different intensified fed-batch processes along with optimized cell culture media for the production of a Mabcalin™ bispecifics. Initially, by leveraging perfusion expansion, intensified fed-batch (IFB) with an inoculation density of 10.3 × 10<sup>6</sup> cells/mL was developed to produce 6.1 g/L of products, compared to 3.9 g/L from the original traditional fed-batch (TFB). Following the IFB conversion, a high-performing production medium, MagniCHO™, was chosen to substitute the original one, which further boosted the titer to 9.1 g/L. The result underscored the significance of developing an optimized cell culture media for intensified cultivation. Furthermore, the approach of ultra-intensified intermittent-perfusion fed-batch was utilized, raising the seeding density to 73.6 × 10<sup>6</sup> cells/mL. A final harvest titer of 24.5 g/L was recorded. Additionally, manufacturing COG was calculated to evaluate how process intensification could lead to improved manufacturing cost-effectiveness, with up to 71 % COG reduction attainable with the UI-IPFB process. This study demonstrated that even for difficult-to-express modalities, applying a strategic development approach including process intensification and media optimization could effectively improve manufacturing efficiency and COG competitiveness.</p></div>\",\"PeriodicalId\":8766,\"journal\":{\"name\":\"Biochemical Engineering Journal\",\"volume\":\"211 \",\"pages\":\"Article 109476\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemical Engineering Journal\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1369703X24002638\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical Engineering Journal","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1369703X24002638","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Stepwise cell culture process intensification for high-productivity and cost-effective commercial manufacturing of a Mabcalin™ bispecifics
Process intensification and media optimization, as a crucial step for improving productivity and manufacturing cost of goods (COG), set the stage for commercialization readiness and redefine the landscape for patient access. This study described a stepwise approach to explore different intensified fed-batch processes along with optimized cell culture media for the production of a Mabcalin™ bispecifics. Initially, by leveraging perfusion expansion, intensified fed-batch (IFB) with an inoculation density of 10.3 × 106 cells/mL was developed to produce 6.1 g/L of products, compared to 3.9 g/L from the original traditional fed-batch (TFB). Following the IFB conversion, a high-performing production medium, MagniCHO™, was chosen to substitute the original one, which further boosted the titer to 9.1 g/L. The result underscored the significance of developing an optimized cell culture media for intensified cultivation. Furthermore, the approach of ultra-intensified intermittent-perfusion fed-batch was utilized, raising the seeding density to 73.6 × 106 cells/mL. A final harvest titer of 24.5 g/L was recorded. Additionally, manufacturing COG was calculated to evaluate how process intensification could lead to improved manufacturing cost-effectiveness, with up to 71 % COG reduction attainable with the UI-IPFB process. This study demonstrated that even for difficult-to-express modalities, applying a strategic development approach including process intensification and media optimization could effectively improve manufacturing efficiency and COG competitiveness.
期刊介绍:
The Biochemical Engineering Journal aims to promote progress in the crucial chemical engineering aspects of the development of biological processes associated with everything from raw materials preparation to product recovery relevant to industries as diverse as medical/healthcare, industrial biotechnology, and environmental biotechnology.
The Journal welcomes full length original research papers, short communications, and review papers* in the following research fields:
Biocatalysis (enzyme or microbial) and biotransformations, including immobilized biocatalyst preparation and kinetics
Biosensors and Biodevices including biofabrication and novel fuel cell development
Bioseparations including scale-up and protein refolding/renaturation
Environmental Bioengineering including bioconversion, bioremediation, and microbial fuel cells
Bioreactor Systems including characterization, optimization and scale-up
Bioresources and Biorefinery Engineering including biomass conversion, biofuels, bioenergy, and optimization
Industrial Biotechnology including specialty chemicals, platform chemicals and neutraceuticals
Biomaterials and Tissue Engineering including bioartificial organs, cell encapsulation, and controlled release
Cell Culture Engineering (plant, animal or insect cells) including viral vectors, monoclonal antibodies, recombinant proteins, vaccines, and secondary metabolites
Cell Therapies and Stem Cells including pluripotent, mesenchymal and hematopoietic stem cells; immunotherapies; tissue-specific differentiation; and cryopreservation
Metabolic Engineering, Systems and Synthetic Biology including OMICS, bioinformatics, in silico biology, and metabolic flux analysis
Protein Engineering including enzyme engineering and directed evolution.